Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Esophageal Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
- Status
- UNKNOWN
- Phase
- PHASE1
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC
- Status
- UNKNOWN
- Phase
- N/A
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Status
- RECRUITING
- Phase
- PHASE2
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
- Status
- UNKNOWN
- Phase
- PHASE2
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
- Status
- UNKNOWN
- Phase
- NA
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
- Status
- UNKNOWN
- Phase
- PHASE2
RAPA-201 Therapy of Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
- Status
- RECRUITING
- Phase
- PHASE3
Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.
- Status
- UNKNOWN
- Phase
- PHASE2